Gestational diabetes & diabetes in pregnancy
Perinatal Outcomes With Continuous Glucose Monitoring in Gestational Diabetes: A Systematic Review and Meta-Analysis
Pooled result · TIRResult — go to the resultMD 2.52 95% CI 1.37–3.67Authors' conclusion
The CGM use in women with GDM significantly improves time in range and increases the use of pharmacotherapy, but it yields no significant differences in other maternal, neonatal, or glycemic outcomes.
Study context
- Population
- Women with Gestational Diabetes Mellitus (GDM); RCTs from PubMed, Embase, Cochrane Library and ClinicalTrials.gov up to March 2026
- Participants
- 1,639 women12 studies
- Comparison
- Continuous glucose monitoring (CGM) vs control in GDM
- Outcome
- TIR
Pooled result
As reported in the abstract
MD
2.52
95% CI 1.37–3.67
CGMvs Control
MD 2.52 (95% CI 1.37–3.67)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Women requiring pharmacotherapy | 1.15 (1.01–1.32) | |
| 0.512Relative risk (log scale) |
Maternal hemoglobin A1c (HbA1c)
- No significant difference in maternal HbA1c; MD
- −0.11 (−0.24 to 0.01) (95% CI)
Cesarean section
- No significant difference in cesarean section; RR
- 0.97 (0.85 to 1.10) (95% CI)
Large for gestational age
- No significant difference in large for gestational age; RR
- 0.64 (0.40 to 1.02) (95% CI)
Macrosomia
- No significant difference in macrosomia; RR
- 1.13 (0.73 to 1.74) (95% CI)
Neonatal hypoglycemia
- No significant difference in neonatal hypoglycemia; RR
- 0.86 (0.67 to 1.11) (95% CI)
Original publication
Perinatal Outcomes With Continuous Glucose Monitoring in Gestational Diabetes: A Systematic Review and Meta-Analysis. J Diabetes Sci Technol. Published 22 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →